Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13131280 | 0.90 | CASP3 (0.46) | CASP3KMT2AMDM4TP53MDM2 | |
| SCHEMBL30844622 | 0.87 | TLR2 (0.45) | CASP3KMT2AMDM4TP53 | |
| SCHEMBL31591448 | 0.87 | TLR2 (0.45) | CASP3KMT2AMDM4TP53 | |
| SCHEMBL30844647 | 0.85 | CASP3 (0.46) | CASP3KMT2AMDM4TP53MDM2 | |
| SCHEMBL31591450 | 0.85 | CASP3 (0.46) | CASP3KMT2AMDM4TP53MDM2 | |
| SCHEMBL29987626 | 0.85 | CASP3 (0.46) | CASP3MDM4TP53MDM2 | |
| SCHEMBL13131282 | 0.85 | CASP3 (0.46) | CASP3MDM4TP53MDM2 | |
| SCHEMBL29666630 | 0.84 | CASP3 (0.48) | CASP3KMT2AMDM4TP53MDM2 | |
| SCHEMBL29400295 | 0.84 | CASP3 (0.48) | CASP3KMT2AMDM4TP53MDM2 | |
| SCHEMBL1959804 | 0.84 | CASP3 (0.48) | CASP3KMT2AMDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580746-B2 | Amide linkage cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580747-B2 | Cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580747-B2 | Cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2001518-B1 | CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8114844-B2 | Linear and cyclic melanocortin receptor-specific peptidomimetics | PALATIN TECHNOLOGIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | PALATIN TECHNOLOGIES, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7964181-B2 | Amino acid surrogates for peptidic constructs | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7795221-B2 | Linear natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100075895-A1 | Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100035821-A1 | Amide Linkage Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| EP-2004633-A2 | LINEAR NATRIURETIC PEPTIDE CONSTRUCTS | Palatin Technologies, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-2004352-A2 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | Palatin Technologies, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-2001518-A2 | CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS | Palatin Technologies, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007115164-A9 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES INC (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070265206-A1 | Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007115164-A2 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007115175-A2 | CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007115182-A2 | LINEAR NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232546-A1 | Linear Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | ARGLU1, QRFPR, ARG1 | CASP3 3507/4885KMT2A 1546/4885MDM4 2030/4885 |
| US-20070265206-A1 | Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | CASP3 4353/4885KMT2A 3394/4885MDM4 4632/4885 |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | ARGLU1, ARG1, QRFPR | CASP3 3729/4885KMT2A 1061/4885MDM4 2560/4885 |
| US-20100035821-A1 | Amide Linkage Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | CASP3 4143/4885KMT2A 3187/4885MDM4 4876/4885 |
| US-20070232546-A1 | Linear Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | CASP3 4168/4885KMT2A 2397/4885MDM4 4792/4885 |
| US-20100075895-A1 | Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | CASP3 4353/4885KMT2A 3394/4885MDM4 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.